CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) Stock Has Consensus Price Target of $117.00

Shares of CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) have received a consensus recommendation of “Hold” from the five research firms that are currently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $117.00.

A number of equities research analysts have issued reports on CHEOY shares. Jefferies Financial Group lowered CochLear from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Zacks Research upgraded CochLear from a “strong sell” rating to a “hold” rating in a research report on Monday, June 22nd. Royal Bank Of Canada downgraded CochLear from an “outperform” rating to a “sector perform” rating and set a $117.00 target price on the stock. in a research note on Thursday, July 16th. Finally, Canaccord Genuity Group lowered shares of CochLear from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 18th.

CochLear Stock Performance

Shares of CHEOY stock opened at $44.64 on Monday. CochLear has a one year low of $31.82 and a one year high of $98.49. The company’s fifty day moving average price is $47.57 and its 200-day moving average price is $44.78.

CochLear Company Profile

Cochlear Limited is an Australian medical technology company that develops, manufactures and supplies implantable hearing solutions for people with moderate to profound hearing loss. Its products are designed to help restore access to sound for individuals who may not benefit sufficiently from conventional hearing aids.

The company’s product portfolio includes cochlear implants, sound processors, bone-conduction hearing implants and related accessories and services. Cochlear also provides professional support, rehabilitation resources and connectivity solutions for recipients, hearing-health specialists and caregivers.

Founded in 1981 and headquartered in Sydney, Australia, Cochlear traces its origins to research led by Professor Graeme Clark, whose work contributed to the development of the world’s first multichannel cochlear implant.